{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:03:23Z","timestamp":1784124203304,"version":"3.55.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Contrast-enhanced mammography (CEM) is a morphofunctional imaging technique that is gaining interest and acceptance in clinical practice. With increasing use of neoadjuvant therapy (NAT) in breast cancer and of precision medicine, the need for equitable access to appropriate high-quality advanced imaging for monitoring response has become ever more relevant. CEM is an imaging alternative for NAT monitoring, with encouraging initial results and a good logistical profile. In this educational review from a practical perspective, we explore key aspects for response assessment of NAT and CEM roles in this setting, based on relevant literature and the authors\u2019 clinical experience. Pearls and pitfalls, as well as opportunities and challenges for NAT monitoring with CEM, will be approached from the perspectives of the radiologist, the oncologist, the surgeon, the pathologist, and the patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Critical relevance statement<\/jats:title>\n                    <jats:p>The early experience with CEM in the NAT setting is positive, encouraging its further development, not only from the radiologist's view but also from a broad multidisciplinary perspective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>CEM seems to be non-inferior to MRI for response evaluation and preoperative re-staging after NAT.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>CEM may predict and monitor in vivo chemosensitivity during NAT.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>CEM may allow a greater patient flow rate compared to MRI.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13244-026-02294-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:27:28Z","timestamp":1784114848000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Contrast-enhanced mammography in the setting of neoadjuvant therapy from a multidisciplinary perspective"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-8526","authenticated-orcid":false,"given":"L\u00edgia","family":"Pires-Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concei\u00e7\u00e3o","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Guimar\u00e3es-Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Teresa","family":"Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donz\u00edlia","family":"Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Manuel","family":"Henrique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"key":"2294_CR1","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA et al (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39:1485\u20131505","journal-title":"J Clin Oncol"},{"key":"2294_CR2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1093\/oxfordjournals.jncimonographs.a003469","volume":"30","author":"N Wolmark","year":"2001","unstructured":"Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from national surgical adjuvant breast and bowel project B-18. J Natl Cancer Inst Monogr 30:96\u2013102","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2294_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172","journal-title":"Lancet"},{"key":"2294_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1200\/JCO.1999.17.2.460","volume":"17","author":"HM Kuerer","year":"1999","unstructured":"Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460\u2013469","journal-title":"J Clin Oncol"},{"key":"2294_CR5","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","volume":"34","author":"AS Caudle","year":"2016","unstructured":"Caudle AS, Yang WT, Krishnamurthy S et al (2016) Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 34:1072\u20131078","journal-title":"J Clin Oncol"},{"key":"2294_CR6","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1245\/s10434-011-1919-5","volume":"18","author":"R Croshaw","year":"2011","unstructured":"Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T (2011) Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol 18:3160\u20133163","journal-title":"Ann Surg Oncol"},{"key":"2294_CR7","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/bjc.2013.473","volume":"109","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Macaskill P, Irwig L et al (2013) Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer 109:1528\u20131536","journal-title":"Br J Cancer"},{"key":"2294_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-017-0899-1","volume":"19","author":"V Iotti","year":"2017","unstructured":"Iotti V, Ravaioli S, Vacondio R et al (2017) Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast Cancer Res 19:106","journal-title":"Breast Cancer Res"},{"key":"2294_CR9","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1245\/s10434-018-6413-x","volume":"25","author":"BK Patel","year":"2018","unstructured":"Patel BK, Hilal T, Covington M et al (2018) Contrast-enhanced spectral mammography is comparable to MRI in the assessment of residual breast cancer following neoadjuvant systemic therapy. Ann Surg Oncol 25:1350\u20131356","journal-title":"Ann Surg Oncol"},{"key":"2294_CR10","first-page":"8531916","volume":"8","author":"FR Barra","year":"2018","unstructured":"Barra FR, Sobrinho AB, Barra RR et al (2018) Contrast-enhanced mammography (CEM) for detecting residual disease after neoadjuvant chemotherapy: a comparison with breast magnetic resonance imaging (MRI). Biomed Res Int 8:8531916","journal-title":"Biomed Res Int"},{"key":"2294_CR11","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2214\/AJR.22.27756","volume":"219","author":"D Bernardi","year":"2022","unstructured":"Bernardi D, Vatteroni G, Acquaviva A et al (2022) Contrast-enhanced mammography versus MRI in the evaluation of neoadjuvant therapy response in patients with breast cancer: a prospective study. AJR Am J Roentgenol 219:884\u2013894","journal-title":"AJR Am J Roentgenol"},{"key":"2294_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s10549-023-06865-8","volume":"198","author":"MP Hogan","year":"2023","unstructured":"Hogan MP, Horvat JV, Ross DS et al (2023) Contrast-enhanced mammography in the assessment of residual disease after neoadjuvant treatment. Breast Cancer Res Treat 198:349\u2013359","journal-title":"Breast Cancer Res Treat"},{"key":"2294_CR13","doi-asserted-by":"publisher","first-page":"20200301","DOI":"10.1259\/bjr.20200301","volume":"93","author":"S Tang","year":"2020","unstructured":"Tang S, Xiang C, Yang Q (2020) The diagnostic performance of CESM and CE-MRI in evaluating the pathological response to neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. Br J Radiol 93:20200301","journal-title":"Br J Radiol"},{"key":"2294_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-023-07034-7","volume":"202","author":"M Kaiyin","year":"2023","unstructured":"Kaiyin M, Lingling T, Leilei T, Wenjia L, Bin J (2023) Head-to-head comparison of contrast-enhanced mammography and contrast-enhanced MRI for assessing pathological complete response to neoadjuvant therapy in patients with breast cancer: a meta-analysis. Breast Cancer Res Treat 202:1\u20139","journal-title":"Breast Cancer Res Treat"},{"key":"2294_CR15","doi-asserted-by":"publisher","first-page":"e240117","DOI":"10.1148\/rycan.240117","volume":"7","author":"L Pires-Gon\u00e7alves","year":"2025","unstructured":"Pires-Gon\u00e7alves L, Aguiar AT, Leal C, Guimar\u00e3es-Santos A, Abreu M, Henrique R (2025) Prospective evaluation of contrast-enhanced mammography for early prediction of pathologic response after neoadjuvant therapy. Radiol Imaging Cancer 7:e240117","journal-title":"Radiol Imaging Cancer"},{"key":"2294_CR16","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/diagnostics16040640","volume":"16","author":"O Acar","year":"2026","unstructured":"Acar O, A\u00e7ar \u00c7R, Orguc \u0130S, Ekinci F, Sahbazlar M, Erdo\u011fan AP (2026) Contrast-enhanced mammography vs. breast MRI for assessing neoadjuvant chemotherapy response: a prospective clinical comparison study. Diagnostics (Basel) 16:640","journal-title":"Diagnostics (Basel)"},{"key":"2294_CR17","doi-asserted-by":"publisher","first-page":"W231","DOI":"10.2214\/AJR.16.17239","volume":"208","author":"BK Patel","year":"2017","unstructured":"Patel BK, Gray RJ, Pockaj BA (2017) Potential cost savings of contrast-enhanced digital mammography. AJR Am J Roentgenol 208:W231\u2013W237","journal-title":"AJR Am J Roentgenol"},{"key":"2294_CR18","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/02841851221144021","volume":"64","author":"L Pires-Gon\u00e7alves","year":"2023","unstructured":"Pires-Gon\u00e7alves L, Henriques Abreu M, Ferr\u00e3o A et al (2023) Patient perspectives on repeated contrast-enhanced mammography and magnetic resonance during neoadjuvant chemotherapy of breast cancer. Acta Radiol 64:1816\u20131822","journal-title":"Acta Radiol"},{"key":"2294_CR19","doi-asserted-by":"publisher","first-page":"112351","DOI":"10.1016\/j.ejrad.2025.112351","volume":"192","author":"F Pediconi","year":"2025","unstructured":"Pediconi F, Moffa G (2025) Contrast-enhanced mammography: bridging the research gaps and defining the future. Eur J Radiol 192:112351","journal-title":"Eur J Radiol"},{"key":"2294_CR20","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1148\/radiol.2019192094","volume":"294","author":"MS Davenport","year":"2020","unstructured":"Davenport MS, Perazella MA, Yee J et al (2020) Use of intravenous iodinated contrast media in patients with kidney disease: consensus statements from the American College of Radiology and the National Kidney Foundation. Radiology 294:660\u2013668","journal-title":"Radiology"},{"key":"2294_CR21","doi-asserted-by":"publisher","first-page":"W528","DOI":"10.2214\/AJR.05.1944","volume":"187","author":"C Dromain","year":"2006","unstructured":"Dromain C, Balleyguier C, Muller S et al (2006) Evaluation of tumor angiogenesis of breast carcinoma using contrast-enhanced digital mammography. AJR Am J Roentgenol 187:W528\u2013W537","journal-title":"AJR Am J Roentgenol"},{"key":"2294_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13244-019-0756-0","volume":"10","author":"M Zanardo","year":"2019","unstructured":"Zanardo M, Cozzi A, Trimboli RM et al (2019) Technique, protocols and adverse reactions for contrast-enhanced spectral mammography (CESM): a systematic review. Insights Imaging 10:76","journal-title":"Insights Imaging"},{"key":"2294_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1148\/radiol.12121084","volume":"266","author":"MS Jochelson","year":"2013","unstructured":"Jochelson MS, Dershaw DD, Sung JS et al (2013) Bilateral contrast-enhanced dual-energy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology. 266:743\u2013751","journal-title":"Radiology."},{"key":"2294_CR24","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00404-015-3693-2","volume":"292","author":"M Daniaux","year":"2015","unstructured":"Daniaux M, De Zordo T, Santner W et al (2015) Dual-energy contrast-enhanced spectral mammography (CESM). Arch Gynecol Obstet 292:739\u2013747","journal-title":"Arch Gynecol Obstet"},{"key":"2294_CR25","unstructured":"Pires-Gon\u00e7alves L, Leal C, Ferr\u00e3o A et al (2019) Desempenho da CESM na predi\u00e7\u00e3o da resposta \u00e0 NAC\u2014resultados preliminares. XVIII Jornadas de Senologia\u2014abordagem da doen\u00e7a residual ap\u00f3s quimioterapia prim\u00e1ria, October 2019, Carvoeiro, Portugal"},{"key":"2294_CR26","unstructured":"Pires-Gon\u00e7alves L, Guimar\u00e3es dos Santos A, Aguiar AT et al (2019) Dados log\u00edsticos do desempenho da CESM na predi\u00e7\u00e3o da resposta \u00e0 NAC. XVIII Jornadas de Senologia\u2014abordagem da doen\u00e7a residual ap\u00f3s quimioterapia prim\u00e1ria, Carvoeiro"},{"key":"2294_CR27","unstructured":"European Commission, Directorate-General for Health and Consumers, Karsa, L, Holland, R, Broeders, M et al (2013) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn supplements (Karsa L, Holland R, Broeders M et al). Publications Office, 2013. https:\/\/data.europa.eu\/doi\/10.2772\/13196"},{"key":"2294_CR28","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2214\/AJR.09.2520","volume":"193","author":"CH Hunt","year":"2009","unstructured":"Hunt CH, Hartman RP, Hesley GK (2009) Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 193:1124\u20131127","journal-title":"AJR Am J Roentgenol"},{"key":"2294_CR29","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2015150805","volume":"275","author":"E Kanal","year":"2015","unstructured":"Kanal E, Tweedle MF (2015) Residual or retained gadolinium: practical implications for radiologists and our patients. Radiology 275:630\u2013634","journal-title":"Radiology"},{"key":"2294_CR30","unstructured":"National Clinical Practice Guidelines in Oncology (NCCNN guidelines): breast cancer, version 4.2023. Available via http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site"},{"key":"2294_CR31","unstructured":"Hortobagyi GN, Connoly JL, D\u2019Orsi CJ et al (2017) Breast. In: AJCC cancer staging manual, 8th edn. Springer, Cham, pp 589\u2013636"},{"key":"2294_CR32","unstructured":"FDA. Pathological complete response in neoadjuvant treatment of high risk early-stage breast cancer: use as an endpoint to support accelerated approval. Food and Drug Administration, 2020. Available via FDA. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/pathological-complete-response-neoadjuvant-treatment-high-risk-early-stage-breast-cancer-use.Published. Accessed 31 Jan 2024"},{"key":"2294_CR33","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L et al (2023) Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol 41:4433\u20134442","journal-title":"J Clin Oncol"},{"key":"2294_CR34","doi-asserted-by":"publisher","first-page":"105825","DOI":"10.1016\/j.humpath.2025.105825","volume":"162","author":"GR Bean","year":"2025","unstructured":"Bean GR, Calhoun BC (2025) Current concepts and controversies in post-neoadjuvant breast pathology. Hum Pathol 162:105825","journal-title":"Hum Pathol"},{"key":"2294_CR35","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"2294_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/jncimonographs\/lgv021","volume":"2015","author":"V Semiglazov","year":"2015","unstructured":"Semiglazov V (2015) RECIST for response (clinical and imaging) in neoadjuvant clinical trials in operable breast cancer. J Natl Cancer Inst Monogr 2015:21\u201323","journal-title":"J Natl Cancer Inst Monogr"},{"key":"2294_CR37","unstructured":"Lee CH, Phillips J, Sung JS, Lewin JM, Newell MS (2022) ACR BI-RADS\u00ae Atlas-mammography contrast enhanced mammography (CEM): a supplement to ACR BI-RADS\u00ae mammography 2013. American College of Radiology, Reston, 2022"},{"key":"2294_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s41747-024-00525-2","volume":"8","author":"C Kremser","year":"2024","unstructured":"Kremser C, Gruber L, Dietzel M, Amort B, Santner W, Daniaux M (2024) Quantification of breast biopsy clip marker artifact on routine breast MRI sequences: a phantom study. Eur Radiol Exp 8:128","journal-title":"Eur Radiol Exp"},{"key":"2294_CR39","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.7150\/jca.98597","volume":"15","author":"JEM Theunissen","year":"2024","unstructured":"Theunissen JEM, van Haaren ERM, Frotscher CNA et al (2024) Combining contrast-enhanced mammography and radioactive-free magnetic seed localization of non-palpable breast tumors: a feasibility study. J Cancer 15:6177\u20136184","journal-title":"J Cancer"},{"key":"2294_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1148\/rg.2021200134","volume":"41","author":"B Reig","year":"2021","unstructured":"Reig B, Lewin AA, Du L et al (2021) Breast MRI for evaluation of response to neoadjuvant therapy. Radiographics 41:665\u2013679","journal-title":"Radiographics"},{"key":"2294_CR41","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.diii.2021.11.001","volume":"103","author":"L Pires-Gon\u00e7alves","year":"2022","unstructured":"Pires-Gon\u00e7alves L, Abreu MH, Aguiar AT, Guimar\u00e3es Dos Santos A, Ferr\u00e3o A, Henrique R (2022) Size reduction and decreased enhancement of benign breast fibroadenoma on contrast-enhanced mammography during neoadjuvant chemotherapy. Diagn Interv Imaging 103:121\u2013122","journal-title":"Diagn Interv Imaging"},{"key":"2294_CR42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1148\/radiol.2015150006","volume":"277","author":"S Schrading","year":"2015","unstructured":"Schrading S, Kuhl CK (2015) Breast cancer: influence of taxanes on response assessment with dynamic contrast-enhanced MR imaging. Radiology 277:687\u2013696","journal-title":"Radiology"},{"key":"2294_CR43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2214\/AJR.19.22022","volume":"214","author":"SX Sun","year":"2020","unstructured":"Sun SX, Moseley TW, Kuerer HM, Yang WT (2020) Imaging-based approach to axillary lymph node staging and sentinel lymph node biopsy in patients with breast cancer. AJR Am J Roentgenol 214:249\u2013258","journal-title":"AJR Am J Roentgenol"},{"key":"2294_CR44","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1097\/SLA.0000000000004356","volume":"273","author":"S Samiei","year":"2021","unstructured":"Samiei S, de Mooij CM, Lobbes MBI, Keymeulen KBMI, van Nijnatten TJA, Smidt ML (2021) Diagnostic performance of noninvasive imaging for assessment of axillary response after neoadjuvant systemic therapy in clinically node-positive breast cancer: a systematic review and meta-analysis. Ann Surg 273:694\u2013700","journal-title":"Ann Surg"},{"key":"2294_CR45","doi-asserted-by":"publisher","first-page":"S462","DOI":"10.1016\/j.jacr.2017.08.037","volume":"14","author":"PJ Slanetz","year":"2017","unstructured":"Expert Panel on Breast Imaging, Slanetz PJ, Moy L, Baron P et al (2017) ACR appropriateness criteria\u00ae monitoring response to neoadjuvant systemic therapy for breast cancer. J Am Coll Radiol 14:S462\u2013S475","journal-title":"J Am Coll Radiol"},{"key":"2294_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000534670","volume":"18","author":"M Graeser","year":"2023","unstructured":"Graeser M, Gluz O (2023) HER2+ early breast cancer: from escalation via targeted and post-neoadjuvant treatment to de-escalation. Breast Care (Basel) 18:455\u2013463","journal-title":"Breast Care (Basel)"},{"key":"2294_CR47","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1245\/s10434-015-4502-7","volume":"22","author":"MS Jochelson","year":"2015","unstructured":"Jochelson MS, Lampen-Sachar K, Gibbons G et al (2015) Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy? Ann Surg Oncol 22:1490\u20131495","journal-title":"Ann Surg Oncol"},{"key":"2294_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.path.2017.09.010","volume":"11","author":"V Bossuyt","year":"2018","unstructured":"Bossuyt V (2018) Processing and reporting of breast specimens in the neoadjuvant setting. Surg Pathol Clin 11:213\u2013230","journal-title":"Surg Pathol Clin"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-026-02294-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-026-02294-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:03:23Z","timestamp":1784120603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13244-026-02294-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1186\/s13244-026-02294-5","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.P.-G. is a member of the Scientific Editorial Board of Insights into Imaging and, as such, did not participate in the selection or review processes for this article. The remaining authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All individuals whose data or information are used in the manuscript have given their consent for its publication. The article is based on the author's clinical experience and on data collected in a single-center study that was approved by IPO-Porto Institutional Ethics Committee (CES: 43\/2018).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"184"}}